| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 31D90UKP5Y |
| InChI Key | YPQLFJODEKMJEF-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H11F3N2O4 |
| Molecular Weight | 292.21 |
| AlogP | 2.32 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 92.47 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 20.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Oxidoreductase
|
- | - | - | - | 8 | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 3
|
- | 2013 | - | - | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 4
|
- | 15-7690 | - | 2-430 | 60-95 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Prostatic Neoplasms, Castration-Resistant | 2 | D064129 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL491 |
| EPA CompTox | DTXSID8033562 |
| FDA SRS | 31D90UKP5Y |
| Human Metabolome Database | HMDB0060949 |
| Guide to Pharmacology | 2862 |
| KEGG | C14204 |
| PDB | HFT |
| SureChEMBL | SCHEMBL3079778 |
| ZINC | ZINC000004655055 |